The article discusses the impact of excessive protein intake on kidney health, the link between stress and blood sugar levels in diabetics, and a case study on the potential benefits of psilocybin ('magic mushrooms') for advanced Alzheimer's disease.
Christian Angermayer, a billionaire known for biotech and bitcoin, is launching the "Enhanced Games," which permits performance-enhancing drugs. He believes this is the future of sport, despite criticism from anti-doping authorities.
Participants took 25mg of psilocybin, reporting deeper psychological insight and better wellbeing a month laterA single dose of psilocybin, the active ingredient in magic mushrooms, can induce anatomical changes in the brain, according to research among people who took the psychedelic compound for the first time.Scientists spotted apparent changes in the brain’s structure which were still apparent a month after healthy volunteers took the drug. If confirmed, they may help explain the therapeutic effects that psychedelics can have on anxiety, depression and addiction, researchers said. Continue reading...
President Trump announces Dr. Nicole Saphier as his nominee for U.S. surgeon general, replacing Dr. Casey Means whose confirmation stalled in the Senate for months over concerns about her controversial stances on vaccines and other issues. Saphier is a breast radiologist at Memorial Sloan Kettering Cancer Center and Fox News contributor since 2018.
The Food and Drug Administration said on Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach. President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed access and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal...
President Donald Trump signed an executive order on Saturday aimed at accelerating psychedelics research, directing agencies to expand clinical trials and Right to Try access for psilocybin, MDMA and ibogaine. The order leaves drug scheduling unchanged and comes amid stalled cannabis rescheduling efforts, raising questions about whether psychedelics will face similar federal delays. Psychedelic stocks rallied significantly following the announcement, with AtaiBeckley jumping roughly 25%.
